TwitterRSSFacebookDirectors Blog
  Disorders A - Z:   A    B   C    D    E    F    G    H    I    J    K    L    M    N    O    P    Q    R    S    T    U    V    W    X    Y    Z

Skip secondary menu

Funding News - Bench to Bedside Research on Type 1 Diabetes and Its Complications Requested

Archive folder iconHistorical Data

  • The information on this page is for historical and research purposes only.
  • For the most current NINDS funding announcements, please see the NINDS list of Active Funding Initiatives or Follow Us on Twitter for the latest funding news.

The National Institute of Neurological Disorders and Stroke (NINDS) requests applications for bench to bedside research on type 1 diabetes and its complications. This request is made together with 5 other components of the National Institutes of Health (NIH).*

Diabetes is difficult to control with the current therapies available. As a result, some patients with type 1 diabetes suffer devastating consequences including accelerated cardiovascular and peripheral vascular diseases, nephropathy, retinopathy, neuropathy, oral diseases, and premature death. The overall objective of the request for applications (RFA) is to stimulate partnerships between basic and clinical scientists with the goal of translating advances in the understanding of the molecular basis of type 1 diabetes into new therapies for the disease.

Examples of potential areas of research interest include: development and/or testing of strategies to retard or reverse the immune and/or inflammatory processes leading to the development of type 1 diabetes and its macro- and microvascular complications; development of improved approaches to pancreas harvesting and/or islet isolation, evaluation, or administration; development and/or testing of strategies to develop new or improved sources of beta cells/islets or to enhance the regeneration or viability of beta cells/islets; development of non-human primate or other animal models of type 1 diabetes or its complications which closely parallel the human disease; identification and/or evaluation of surrogate endpoints which can be used in clinical trials to prevent, delay, or reverse type 1 diabetes and its complications; and development or testing of innovative pharmacological agents and interventions to prevent or halt the progression of type 1 diabetes or its complications.


For more information, potential applicants should contact Dr. Paul Nichols, Program Director, Systems and Cognitive Neuroscience Cluster, NINDS, Neuroscience Center, 6001 Executive Boulevard, Room 2108, Bethesda, MD 20892; telephone: 301-496-9964; fax: 301-401-2060; e-mail:

*For a full list of supporting NIH components and a more detailed description of this request for applications, please visit the NIH web site at: